Results 181 to 190 of about 78,892 (304)

Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Immunosuppressive disease was associated with reduced overall survival, while anticoagulant use was linked to prolonged progression‐free survival in advanced cutaneous squamous cell carcinoma treated with immune checkpoint inhibitors. Host‐related factors may modulate immunotherapy efficacy and warrant prospective validation.
Glenn Geidel, Sabrina Bänsch, Laura Adam, Nathan Fekade, Alessandra Rünger, Tim Zell, Daniel J. Smit, Julian Kött, Isabel Heidrich, Michael Weichenthal, Selma Ugurel, Ulrike Leiter, Peter Mohr, Alexandra Geusau, Stephan Grabbe, Markus V. Heppt, Ralf Gutzmer, Jochen Utikal, Jan‐Christoph Simon, Sebastian Haferkamp, Laura Susok, Bastian Schilling, Edgar Dippel, Imke von Wasielewski, Jessica C. Hassel, Carola Berking, Stefan W. Schneider, Christoffer Gebhardt   +27 more
wiley   +1 more source

Calcium Signaling Dysregulation as a Convergent Mechanism in Anesthetic-Induced Developmental Neurotoxicity. [PDF]

Drug Des Devel Ther
Dong C, Zhou H, Chen X, Zhou H, Hamdan H.   +4 more
europepmc   +1 more source

Long‐term efficacy of abrocitinib in patients with moderate‐to‐severe atopic dermatitis to 2 years

Journal of the European Academy of Dermatology and Venereology, EarlyView.
JADE EXTEND is an ongoing phase 3, long‐term extension study of previous abrocitinib trials. Patients were adults and adolescents ≥12 years with moderate‐to‐severe atopic dermatitis. Long‐term abrocitinib treatment resulted in clinically meaningful outcomes and improvements in patient‐reported outcomes up to Week 112 in patients with moderate‐to‐severe
Melinda J. Gooderham, Jonathan I. Silverberg, Marjolein De Bruin‐Weller, Leon Kircik, Diamant Thaçi, Zuotao Zhao, Fernando Valenzuela, Toshifumi Nomura, Andrew Selfridge, Dorothy Fan, Daniela E. Myers, Pinaki Biswas, Saleem A. Farooqui, Melissa Watkins, Herwig Koppensteiner   +14 more
wiley   +1 more source

Kujiol A Inhibits Interferon-γ and Interleukin-2 Expression and the NFATc2 Interaction with Their Promoters in T Cells. [PDF]

Molecules
Yodweerapong T, Yamaguchi R, Nakao A, Kitajima S, Shiba T, Kimura KI, Kataoka T.   +6 more
europepmc   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

Journal of the European Academy of Dermatology and Venereology, EarlyView.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta, Julia Steriopoulos, Vasiliki Economopoulos, Paradi Mirmirani, Vincent Piguet   +4 more
wiley   +1 more source

Genetic and pharmacologic inhibition of calcineurin reduces biofilm formation by the pathogenic fungus Trichosporon asahii in an in vivo silkworm infection model. [PDF]

PLoS One
Matsumoto Y, Shimizu Y, Nakayama M, Takizawa M, Kurakado S, Sugita T.   +5 more
europepmc   +1 more source

Practical recommendations for seborrheic dermatitis management: An expert consensus

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This modified Delphi study established expert consensus on Seborrheic Dermatitis management. Key findings prioritize combined topical antifungal and anti‐inflammatory therapy for both acute flares and long‐term maintenance. The consensus also provides a clear framework for escalating to systemic treatment in extensive or refractory cases.
L. Naldi, A. Kyrgidis, G. S. Tiplica, M. A. de Rie, D. Tatsis, P. Gisondi, D. Ioannides, O. Chosidow, M. Deleuran, the Delphi SD study experts   +9 more
wiley   +1 more source

Topical Pimecrolimus for Treatment-Refractory Tazarotene-Induced Photosensitive Facial Erosions. [PDF]

Cureus
Sanjabi T, Memari K, Rodriguez SA, Manuel J, Cohen P, Williams S.   +5 more
europepmc   +1 more source

Incidence of cutaneous lupus erythematosus and systemic progression: A Nationwide study in Korea

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This nationwide study reports a cutaneous lupus erythematosus (CLE) incidence of 3.98/100,000 person‐years. CLE was associated with an increased risk of actinic keratosis and skin cancer. Progression to SLE clustered within 5 years after CLE diagnosis, with a 5‐year cumulative incidence of 11.4%, supporting a risk‐stratified follow‐up approach during ...
Seon Young Song, Jiyeong Kim, Yu‐Mi Kim, Joo Yeon Ko   +3 more
wiley   +1 more source

Pediatric lichen sclerosus: a self-limited disease? A long-term follow-up case series. [PDF]

An Bras Dermatol
Nogueira CM, Azevedo F, Lisboa C.
europepmc   +1 more source